{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T02:42:41Z","timestamp":1794192161008,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93486-4","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T19:43:46Z","timestamp":1741722226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Melatonin suppresses PD-L1 expression and exerts antitumor activity in hepatocellular carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Rui","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-guo","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-zhen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-heng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ming","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"3","key":"93486_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"93486_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown, Z. J. et al. Management of hepatocellular carcinoma: A review. JAMA Surg. 158 (4), 410\u2013420. https:\/\/doi.org\/10.1001\/jamasurg.2022.7989 (2023).","journal-title":"JAMA Surg."},{"key":"93486_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1323581","author":"L Hao","year":"2023","unstructured":"Hao, L. et al. The current status and future of PD-L1 in liver cancer. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1323581 (2023).","journal-title":"Front. Immunol."},{"issue":"1","key":"93486_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12964-023-01063-x","volume":"21","author":"A Watterson","year":"2023","unstructured":"Watterson, A. & Coelho, M. A. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. Cell. Commun. Signal. 21 (1), 45. https:\/\/doi.org\/10.1186\/s12964-023-01063-x (2023).","journal-title":"Cell. Commun. Signal."},{"issue":"1","key":"93486_CR5","first-page":"1","volume":"10","author":"X Ju","year":"2020","unstructured":"Ju, X., Zhang, H., Zhou, Z. & Wang, Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. Am. J. Cancer Res. 10 (1), 1\u201311 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"93486_CR6","doi-asserted-by":"publisher","first-page":"591188","DOI":"10.3389\/fphar.2020.591188","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Shi, H., Meng, H., Xu, J. & Editorial Targeting the PD-1\/PD-L1 Cancer immune evasion axis: challenges and emerging strategies. Front. Pharmacol. 11, 591188. https:\/\/doi.org\/10.3389\/fphar.2020.591188 (2020).","journal-title":"Front. Pharmacol."},{"key":"93486_CR7","doi-asserted-by":"publisher","unstructured":"Wu, R. et al. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression. Sci Rep. ;13(1):16998.dio: (2023). https:\/\/doi.org\/10.1038\/s41598-023-42948-8","DOI":"10.1038\/s41598-023-42948-8"},{"key":"93486_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev-med-042220-021121","volume":"73","author":"RC Sperandio","year":"2022","unstructured":"Sperandio, R. C., Pestana, R. C., Miyamura, B. V. & Kaseb, A. O. Hepatocellular carcinoma immunotherapy. Annu. Rev. Med. 73, 267\u2013278. https:\/\/doi.org\/10.1146\/annurev-med-042220-021121 (2022).","journal-title":"Annu. Rev. Med."},{"key":"93486_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1070961","author":"Q Li","year":"2022","unstructured":"Li, Q., Han, J., Yang, Y. & Chen, Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1070961 (2022).","journal-title":"Front. Immunol."},{"key":"93486_CR10","doi-asserted-by":"publisher","unstructured":"Chao, Y. C. et al. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer. Int J Mol Sci. ;22(11).dio: (2021). https:\/\/doi.org\/10.3390\/ijms22115649","DOI":"10.3390\/ijms22115649"},{"issue":"7","key":"93486_CR11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/cas.15338","volume":"113","author":"X Luo","year":"2022","unstructured":"Luo, X. et al. Melatonin inhibits EMT and PD-L1 expression through the ERK1\/2\/FOSL1 pathway and regulates anti-tumor immunity in HNSCC. Cancer Sci. 113 (7), 2232\u20132245. https:\/\/doi.org\/10.1111\/cas.15338 (2022).","journal-title":"Cancer Sci."},{"key":"93486_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2023.111917","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. Melatonin enhances anti-tumor immunity by targeting macrophages PD-L1 via exosomes derived from gastric cancer cells. Mol. Cell. Endocrinol. https:\/\/doi.org\/10.1016\/j.mce.2023.111917 (2023).","journal-title":"Mol. Cell. Endocrinol."},{"issue":"3","key":"93486_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1615\/CritRevOncog.2021039881","volume":"26","author":"Y Han","year":"2021","unstructured":"Han, Y. et al. Circadian rhythm and melatonin in liver carcinogenesis: updates on current findings. Crit. Rev. Oncog. 26 (3), 69\u201385. https:\/\/doi.org\/10.1615\/CritRevOncog.2021039881 (2021).","journal-title":"Crit. Rev. Oncog."},{"issue":"5","key":"93486_CR14","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1111\/cas.16103","volume":"115","author":"K Wada","year":"2024","unstructured":"Wada, K. et al. Dietary melatonin and liver cancer incidence in Japan: from the Takayama study. Cancer Sci. 115 (5), 1688\u20131694. https:\/\/doi.org\/10.1111\/cas.16103 (2024).","journal-title":"Cancer Sci."},{"key":"93486_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121530","author":"EMS Cruz","year":"2023","unstructured":"Cruz, E. M. S. et al. Melatonin modulates the Warburg effect and alters the morphology of hepatocellular carcinoma cell line resulting in reduced viability and migratory potential. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2023.121530 (2023).","journal-title":"Life Sci."},{"key":"93486_CR16","doi-asserted-by":"publisher","unstructured":"Elmahallawy, E. K., Mohamed, Y., Abdo, W. & Yanai, T. Melatonin and Mesenchymal Stem Cells as a Key for Functional Integrity for Liver Cancer Treatment. Int J Mol Sci. ;21(12).dio: (2020). https:\/\/doi.org\/10.3390\/ijms21124521","DOI":"10.3390\/ijms21124521"},{"key":"93486_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10010103","author":"P Fern\u00e1ndez-Palanca","year":"2021","unstructured":"Fern\u00e1ndez-Palanca, P. et al. Melatonin as an antitumor agent against liver cancer: an updated systematic review. Antioxid. (Basel). https:\/\/doi.org\/10.3390\/antiox10010103 (2021).","journal-title":"Antioxid. (Basel)"},{"issue":"8","key":"93486_CR18","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.31193","volume":"142","author":"K Kaji","year":"2018","unstructured":"Kaji, K. et al. Sodium glucose cotransporter 2 inhibitor Canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int. J. Cancer. 142 (8), 1712\u20131722. https:\/\/doi.org\/10.1002\/ijc.31193 (2018).","journal-title":"Int. J. Cancer"},{"key":"93486_CR19","doi-asserted-by":"publisher","unstructured":"Mossenta, M., Busato, D., Dal Bo, M. & Toffoli, G. Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers (Basel). ;12(6).dio: (2020). https:\/\/doi.org\/10.3390\/cancers12061668","DOI":"10.3390\/cancers12061668"},{"key":"93486_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102458","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism. Redox Biol. https:\/\/doi.org\/10.1016\/j.redox.2022.102458 (2022).","journal-title":"Redox Biol."},{"key":"93486_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","author":"Q Tang","year":"2022","unstructured":"Tang, Q. et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.964442 (2022).","journal-title":"Front. Immunol."},{"issue":"10","key":"93486_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2174\/1871530320666201201110807","volume":"21","author":"H Ahabrach","year":"2021","unstructured":"Ahabrach, H., El Mlili, N., Errami, M. & Cauli, O. Circadian rhythm and concentration of melatonin in breast Cancer patients. Endocr. Metab. Immune Disord Drug Targets. 21 (10), 1869\u20131881. https:\/\/doi.org\/10.2174\/1871530320666201201110807 (2021).","journal-title":"Endocr. Metab. Immune Disord Drug Targets"},{"key":"93486_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101409","author":"MP Mogavero","year":"2021","unstructured":"Mogavero, M. P., DelRosso, L. M., Fanfulla, F., Bruni, O. & Ferri, R. Sleep disorders and cancer: state of the Art and future perspectives. Sleep. Med. Rev. https:\/\/doi.org\/10.1016\/j.smrv.2020.101409 (2021).","journal-title":"Sleep. Med. Rev."},{"issue":"10","key":"93486_CR24","doi-asserted-by":"publisher","first-page":"6486","DOI":"10.1002\/jcp.26586","volume":"233","author":"K Mortezaee","year":"2018","unstructured":"Mortezaee, K. Human hepatocellular carcinoma: protection by melatonin. J. Cell. Physiol. 233 (10), 6486\u20136508. https:\/\/doi.org\/10.1002\/jcp.26586 (2018).","journal-title":"J. Cell. Physiol."},{"key":"93486_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1007579","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1007579 (2022).","journal-title":"Front. Immunol."},{"key":"93486_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133308","author":"C Chen","year":"2023","unstructured":"Chen, C., Wang, Z., Ding, Y. & Qin, Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1133308 (2023).","journal-title":"Front. Immunol."},{"issue":"4","key":"93486_CR27","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.3892\/ol.2020.11369","volume":"19","author":"Q Wen","year":"2020","unstructured":"Wen, Q., Han, T., Wang, Z. & Jiang, S. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Oncol. Lett. 19 (4), 2595\u20132601. https:\/\/doi.org\/10.3892\/ol.2020.11369 (2020).","journal-title":"Oncol. Lett."},{"issue":"1","key":"93486_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit, T. B. et al. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation. Hepatology 72 (1), 315\u2013. https:\/\/doi.org\/10.1002\/hep.31227 (2020).","journal-title":"Hepatology"},{"issue":"19","key":"93486_CR29","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.2217\/fon-2020-1222","volume":"17","author":"GP Sonpavde","year":"2021","unstructured":"Sonpavde, G. P., Grivas, P., Lin, Y., Hennessy, D. & Hunt, J. D. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. Future Oncol. 17 (19), 2545\u20132558. https:\/\/doi.org\/10.2217\/fon-2020-1222 (2021).","journal-title":"Future Oncol."},{"key":"93486_CR30","doi-asserted-by":"publisher","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. ;6(1):38.dio: (2020). https:\/\/doi.org\/10.1038\/s41572-020-0160-6","DOI":"10.1038\/s41572-020-0160-6"},{"issue":"8","key":"93486_CR31","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to Atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28 (8), 1599\u20131611. https:\/\/doi.org\/10.1038\/s41591-022-01868-2 (2022).","journal-title":"Nat. Med."},{"issue":"2","key":"93486_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1078-0432.CCR-23-2124","volume":"30","author":"TH Patel","year":"2024","unstructured":"Patel, T. H. et al. FDA approval summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. Clin. Cancer Res. 30 (2), 269\u2013273 (2024). .dio:10.1158\/1078\u2009\u2013\u20090432.Ccr-23-2124.","journal-title":"Clin. Cancer Res."},{"key":"93486_CR33","doi-asserted-by":"publisher","unstructured":"Li, S. et al. Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials. Oncoimmunology. ;9(1):1746113.dio: (2020). https:\/\/doi.org\/10.1080\/2162402x.2020.1746113","DOI":"10.1080\/2162402x.2020.1746113"},{"key":"93486_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109244","author":"J Zheng","year":"2022","unstructured":"Zheng, J. et al. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis. Int. Immunopharmacol. https:\/\/doi.org\/10.1016\/j.intimp.2022.109244 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"93486_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820967454","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. A systematic review and Meta-Analysis of Immune-Related adverse events of Anti-PD-1 drugs in randomized controlled trials. Technol. Cancer Res. Treat. https:\/\/doi.org\/10.1177\/1533033820967454 (2020).","journal-title":"Technol. Cancer Res. Treat."},{"key":"93486_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","volume":"64","author":"S Khan","year":"2020","unstructured":"Khan, S. & Gerber, D. E. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Semin Cancer Biol. 64, 93\u2013101. https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.012 (2020).","journal-title":"Semin Cancer Biol."},{"key":"93486_CR37","doi-asserted-by":"publisher","unstructured":"Yang, X., Wang, W. & Ji, T. Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma. Cell Death Dis. ;15(3):186.dio: (2024). https:\/\/doi.org\/10.1038\/s41419-024-06553-5","DOI":"10.1038\/s41419-024-06553-5"},{"key":"93486_CR38","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.2147\/cmar.S257299","volume":"12","author":"P Cui","year":"2020","unstructured":"Cui, P., Jing, P., Liu, X. & Xu, W. Prognostic significance of PD-L1 expression and its Tumor-Intrinsic functions in hypopharyngeal squamous cell carcinoma. Cancer Manag Res. 12, 5893\u20135902. https:\/\/doi.org\/10.2147\/cmar.S257299 (2020).","journal-title":"Cancer Manag Res."},{"key":"93486_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218089","author":"J Eichberger","year":"2020","unstructured":"Eichberger, J. et al. PD-L1 influences cell spreading, migration and invasion in head and neck Cancer cells. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21218089 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"93486_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9289719","author":"C Zeng","year":"2021","unstructured":"Zeng, C. et al. HOXA-AS3 promotes proliferation and migration of hepatocellular carcinoma cells via the miR-455-5p\/PD-L1 Axis. J. Immunol. Res. https:\/\/doi.org\/10.1155\/2021\/9289719 (2021).","journal-title":"J. Immunol. Res."},{"issue":"5","key":"93486_CR41","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3892\/or.2017.5523","volume":"37","author":"F Zhong","year":"2017","unstructured":"Zhong, F., Cheng, X., Sun, S. & Zhou, J. Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells. Oncol. Rep. 37 (5), 3061\u20133067. https:\/\/doi.org\/10.3892\/or.2017.5523 (2017).","journal-title":"Oncol. Rep."},{"key":"93486_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145796","author":"M Rashid","year":"2021","unstructured":"Rashid, M. et al. Up-down regulation of HIF-1\u03b1 in cancer progression. Gene https:\/\/doi.org\/10.1016\/j.gene.2021.145796 (2021).","journal-title":"Gene"},{"key":"93486_CR43","doi-asserted-by":"publisher","unstructured":"Bailey, C. M. et al. Targeting HIF-1\u03b1 abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. J Clin Invest. ;132(9).dio: (2022). https:\/\/doi.org\/10.1172\/jci150846","DOI":"10.1172\/jci150846"},{"key":"93486_CR44","doi-asserted-by":"publisher","unstructured":"Ding, X. C. et al. The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia. J Hematol Oncol. ;14(1):92.dio: (2021). https:\/\/doi.org\/10.1186\/s13045-021-01102-5","DOI":"10.1186\/s13045-021-01102-5"},{"key":"93486_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101618","author":"C Braicu","year":"2019","unstructured":"Braicu, C. et al. A comprehensive review on MAPK: A promising therapeutic target in Cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11101618 (2019).","journal-title":"Cancers (Basel)"},{"key":"93486_CR46","doi-asserted-by":"publisher","unstructured":"Wu, M. et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. ;15(1):24.dio: (2022). https:\/\/doi.org\/10.1186\/s13045-022-01242-2","DOI":"10.1186\/s13045-022-01242-2"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93486-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93486-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:30:04Z","timestamp":1741764604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93486-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93486"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93486-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study has obtained approval from the Ethics Committee of the First Affiliated Hospital of Gannan Medical University (LLSC2023141) and Animal Experiment Ethics Committee of the First Affiliated Hospital of Gannan Medical University (LLSC2023227).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval"}},{"value":"All the listed authors agree to the publication of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"8451"}}